These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16380226)

  • 1. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies.
    Dixon JM; Bundred N
    Eur J Surg Oncol; 2006 Mar; 32(2):123-5. PubMed ID: 16380226
    [No Abstract]   [Full Text] [Related]  

  • 2. Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2006 Jan; 98(2):86-7. PubMed ID: 16418506
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neoadjuvant antihormonal treatment of women with breast cancer].
    Tuxen MK; Kamby C; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
    Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
    Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors for hormonal therapy of early-stage breast cancer.
    Traina TA; Dickler MN
    Curr Opin Investig Drugs; 2004 Jun; 5(6):605-10. PubMed ID: 15242248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 7. Aromatase inhibitors in breast cancer: an overview.
    Altundag K; Ibrahim NK
    Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
    Wheler J; Johnson M; Seidman A
    Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M; Skougaard K; Kamby C; Nielsen DL
    Ugeskr Laeger; 2008 Jun; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract]   [Full Text] [Related]  

  • 10. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen in breast cancer: not so easy to write off.
    Munshi A; Singh P
    Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 17. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.
    Buzdar AU; Cuzick J
    J Clin Oncol; 2005 Nov; 23(33):8544-6; author reply 8546-7. PubMed ID: 16293888
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hormonal therapy in breast cancer].
    Espinós J; Reyna C; de la Cruz S; Oiler C; Hernández A; Fernández Hidalgo O; Santisteban M; García Foncillas J
    Rev Med Univ Navarra; 2008; 52(1):40-8. PubMed ID: 18578196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.